Optimi Health Corp. (OPTH)
| Market Cap | 23.44M +107.5% |
| Revenue (ttm) | 166,105 -53.2% |
| Net Income | -3.87M |
| EPS | -1.20 |
| Shares Out | 5.63M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,631 |
| Open | 4.100 |
| Previous Close | 4.240 |
| Day's Range | 4.100 - 4.406 |
| 52-Week Range | 3.000 - 8.838 |
| Beta | 1.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 31, 2026 |
About OPTH
Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners. The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets. The company also engages in farming, processing, and distribution... [Read more]
Financial Performance
In fiscal year 2025, Optimi Health's revenue was 426,301, an increase of 9.35% compared to the previous year's 389,850. Losses were -3.71 million, -38.50% less than in 2024.
Financial numbers in CAD Financial StatementsNews
Optimi launches standardized microdose psilocybin products for clinical research
Optimi Health (OPTH) announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized…
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocyb...
Psychedelic: Optimi Health completes psilocybin export to the UK
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a psilocybin export, an analyst initiation and a CFO appointment. OPTIMI COMPLETES…
Optimi Health completes first export of naturally derived psilocybin to the UK
Optimi Health (OPTH) announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment comprises…
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization fro...
Optimi Health commences finished ibogaine drug product development
Optimi Health (OPTH) provided an update on its recently announced “Ibogaine Initiative,” stating that Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride and freebase...
Optimi Health secures ibogaine supply
Optimi Health (OPTH) provided an update on its recently announced Ibogaine initiative. Optimi has secured naturally derived ibogaine from two sources, in both hydrochloride and freebase form. Developm...
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD, opi...
Optimi Health completes commercial production of psilocybin capsules
Optimi Health (OPTH) announced the completion of a good manufacturing practice production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed in...
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United S...
Optimi Health Registration statement: Q2 2026
Optimi Health filed a registration statement on May 31, 2026, providing details about a securities offering with the SEC.
Optimi Health Registration statement: Q2 2026
Optimi Health filed a registration statement on May 31, 2026, providing details about a securities offering with the SEC.
Optimi Health reports expanded psychedelic-assisted therapy access in Australia
Optimi Health (OPTH) acknowledged the final recommendations published by the Therapeutic Goods Administration following its targeted consultation on the Authorized Prescriber, or AP, scheme for psiloc...
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psiloc...
Psychedelic: Optimi Health advances natural psilocybin extract
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a production run completion, an IRB approval and a rights expansion. OPTIMI…
Diamond Equity Research Initiates Coverage on Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN)
New York, May 27, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research LLC, an equity research firm with a focus on small capitalization public companies has initiated coverage of Optimi Health Corp. (NAS...
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
The 6% naturally derived extract is set to be encapsulated for use in patients suffering from treatment-resistant depression under Australia's Authorised Prescriber Scheme, where no serious adverse ev...
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused...
SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)
NORTH PALM BEACH, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platf...
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH" Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (th...
Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer o...
Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products
The Company's Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTS...
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focuse...
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated Framework Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE...
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Naturally-Derived 5 mg Psilocybin Capsules Mark the Company's Second Drug in Market Under Australia's Authorised Prescriber Scheme Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - O...